Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Рак молочной железы

Список литературы

  1. Эндокринно-чувствительные опухоли репродуктивной системы: руководство для врачей / [И. В. Высоцкая и др.];- Москва : Спец. изд-во мед. кн. (СИМК), 2014. - 126,
  2. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2017. илл. 250 с.
  3. WHO classification of tumours of the breast. Lakhani, Sunil R; International Agency for Research on Cancer; World Health Organization. Lyon : International Agency for Research on Cancer, 2012. 240 p.
  4. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 7th ed. Sobin L.H., Gospodarowicz M.K., Wittekind Ch., eds. New York: Wiley-Blackwell; 2009.
  5. Members of the Breast Cancer Disease Site Group. Baseline staging tests in primary breast cancer. Hamm C, Tey R, reviewers. Toronto (ON): Cancer Care Ontario; 2011 Nov 1 [Endorsed 2011 Oct 11]. Program in Evidence-based Care Evidence-Based Series No.: 1-14 Version 2 EDUCATION AND INFORMATION 2015. https://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Dat abase/CCO%20Files/PEBC/pebc1-14f.pdf
  6. ICRU Report 50 Journal of the ICRU Issueded:1 November 1999; ICRU Report 83 Journal of the ICRU Vol 10, №1, 2010
  7. Hussain M Cunnick GH Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast--a review. Eur J Surg Oncol. 2011 Apr;37(4):279-89.
  8. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010 Feb 3;102(3):170-8.
  9. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials. Breast. 2009 Jun;18(3):143-9
  10. Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens MH, Bogaerts J, Bartelink H. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012 Apr;13(4):412-9.
  11. Glechner A, Wöckel A, Gartlehner G, Thaler K, Strobelberger M, Griebler U, Kreienberg R. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013 Mar;49(4):812-25.
  12. Fisher B., Anderson S., Bryant J. Twenty-year follow-up of randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiaton for the treatment of invasive breast cancer N Engl j Med 2002;347:1233-124).
  13. Early Breast Cancer Trialists` Collaborative G, Darby S., McGale P. Et al Effect of radiotherapy after breast -conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials Lancet 2011; 378:1707-1716
  14. Haviland JS.,Owen JL, Dewar Ja et al The UK Standartisation of Breast Radiotherapy hypofractionination for treatment (START) of early breast-cancer:10-year follow-up results of two randomized controlled trials Lancet Oncol 2013;14:1086-1094
  15. Bartelink Н., Maingon P. и Portmans P. 20-year results of the randomized «boost» versus «no boost» EORTC 22881-10882 trial The Lancet Oncol. – 2015. – 16(1). – P. 47-46
  16. Joyce DP, Manning A, Carter M, Hill AD, Kell MR, Barry M. Meta-analysis to determine the clinical impact of axillary lymph node dissection in the treatment of invasive breast cancer. Breast Cancer Res Treat. 2015 Sep;153(2):235-40.
  17. Budach et al. Adjuvant radiotherapy of regional lymph nodes in breast cancer – a meta- analisys of randomized trials. Radiation Oncology 2013, 8:267
  18. Newman LA. Management of patients with locally advanced breast cancer. Curr Oncol Rep. 2004 Jan;6(1):53-61. Review.
  19. Loughney L, West MA, Kemp GJ, Grocott MP, Jack S. Exercise intervention in people with cancer undergoing neoadjuvant cancer treatment and surgery: A systematic review. Eur J Surg Oncol. 2016 Jan;42(1):28-38
  20. Budach W, Matuschek C, Bölke E, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of German Society of Radiation Oncology (DEGRO).DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol. 2015 Aug;191(8):623-33.
  21. Стенина М.Б., Жукова Л.Г., Королева И.А., Пароконная А.А., Семиглазова Т.Ю., Тюляндин С.А., Фролова М.А. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. - 2016. - №4. Спецвыпуск 2. – С. 97-122.
  22. Gradishar WJ et al. NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 2. 2016.
  23. Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology 26: 1533–1546, 2015.
  24. Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107–118.
  25. Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436–446.
  26. Moore HCF, Unger JM, Phillips KA et al. Goserelin for ovarian protection during breast- cancer adjuvant chemotherapy. N Engl J Med 2015; 372: 923–932.
  27. Early Breast Cancer Trialists’ Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome in 100,000 randomised women in 123 randomized trials. Lancet 2012; 379: 432–444.
  28. Hart CD, Di Leo A. Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. Breast 2015; 24(Suppl 1): PG 12.02.
  29. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273–1283.
  30. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 2013; 381: 805–816.
  31. Schneeweiss A, Chia S, Hickish T et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278–2284.
  32. Masuda H, Baggerly KA, Wang Y et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19: 5533– 5540.
  33. von Minckwitz G, Hahnen E, Fasching PA et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. J Clin Oncol 2014; 32(5s): abstr 1005.
  34. Tutt A, Ellis P, Kilburn LS et al. TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer CRUK/07/012). Cancer Res Suppl 2014; 75: S3-01.
  35. Jones S, Holmes F, O´Shaughnessey J et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research trial 9735. JCO 2009; 27: 1177-1183.
  36. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. JCO 1990; 8:1483-1496.
  37. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352-22.
  38. Goldhirsch A, Colleoni M, Coates AS et al. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). Ann Oncol 1998; 9: 489-93.
  39. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in adjuvant treatment of breast cancer. N Engl J Med 2008; 258: 1663-1671.
  40. Roche H, Fumoleau P, Spielmann M et al, Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 001 trial. JCO 2006; 24: 5664-5671.
  41. Martin M, Rodriquez-Lescure A, Ruiz A et al. Randomized phase III trial of fluorouracil, epirubicin and cyclophosphamide alone or followed dy paclitaxel for early breast cnacer. J Natl Cancer Inst 2008; 100: 805-814.
  42. Romondi EH, Perez EZ, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
  43. Jones SE, Collea R, Paul D et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group open- label phase II study. Lancet Oncol 2012; 13: 25-32.
  44. Tolaney S, Barry W, Dang C et al. Adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer. N Engl J Med 2016; 372: 134-141
  45. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women locally advanced, inflammatory or early HER2-positive breast cancer (NeoSphere): a randomized multicenter open-label phase II trial. Lancet Oncol 2012; 13: 25-32.
  46. Tevaarwerk AJ, Wang M, Zhao F et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with nodenegative,hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014; 32: 3948–3958.
  47. Ribi K, Luo W, Francis P et al. Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: adjuvant treatment with tamoxifen (T) alone versus T plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). Cancer Res Suppl 2014; S3-09.
  48. Bernhard J, Luo W, Ribi K et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 2015; 32(Suppl 15): #557.
  49. Regan M. Predicting benefit of endocrine therapy. Breast 2015; 24(Suppl 1):PG 11.03.
  50. Viale G, Regan MM, Dell’Orto P et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1–98 randomized trial. Ann Oncol 2011; 22: 2201–2207.
  51. EBCTCG. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient date from randomized trial. Lancet 2015. 386: 1353-1361.
  52. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local- regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. JCO 1997; 15: 2483-2493.
  53. Bonadonna G, Valagussa P, Brambilla C, Ferrari L. Preoperative chemotherapy in operable breast cancer. Lancet 1993; 341: 1485.
  54. Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer—10-year survival data after chemotherapy and hormone therapy. Br J Cancer 1997; 76: 1099–105.
  55. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275–81.
  56. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164–72.
  57. Allevi G, Strina C, Andreis D et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br J Cancer 2013; 108: 1587–1592.
  58. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167– 170.
  59. Dowsett M. Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints. Breast 2015; 24(Suppl 1): PG 8.02.
  60. Goodwin PJ. Obesity and insulin resistance: clinical relevance and research priorities. Breast 2015; 24(Suppl 1): PG 6.03.
  61. Kuss JT, Muss HB, Hoen H et al: Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 1997, 42:265-274.
  62. Klijn JG, Beex LV, Mauriac L et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000, 92:903-911.
  63. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
  64. Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
  65. Thürlimann B, Hess D, Köberle D et al. Anastrozole ('Arimidex') versus tamoxifen as first- line therapy in postmenopausal women with advanced breast cancer: results of the double- blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004, 85:247- 254.
  66. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2606.
  67. Muss HB, Case LD, Atkins JN et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association Study. J Clin Oncol 1994, 12:1630-1638.
  68. Rugo HS, Rumble RB, Macrae E et al. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Published Ahead of Print on May 23, 2016 as 10.1200/JCO.2016.67.1487.
  69. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone- receptorpositive advanced breast cancer. N Engl J Med 366:520-529, 2012.
  70. Chan S, Friedrichs K, Noel D et al. 303 Study Group: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341-2454.
  71. Bastholt L, Dalmark M, Gjedde SB et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996, 14:1146-1166.
  72. O'Brien ME, Wigler N, Inbar M et al. CAELYX Breast Cancer Study Group: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
  73. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005, 23:5542- 5551.
  74. Seidman AD, Berry D, Cirrincione C et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26:1642-1649/
  75. Perez EA, Vogel CL, Irwin DH et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001, 19:4216-4223.
  76. Burris HA: Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 1999, 26(3 suppl 9):1-6.
  77. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000, 18:1212-1219.
  78. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin- bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
  79. Gradishar WJ, Krasnojon D, Cheporov S et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009, 27:3611-3619.
  80. Zelek L, Barthier S, Riofrio M et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001, 92:2267-2272.
  81. Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS- 247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007, 25:3415-3420.
  82. Rivera E, Gomez H: Chemotherapy resistance in metastatic breast cancer:the evolving role of ixabepilone. Breast Cancer Res 2010, 12(suppl 2):1-12.
  83. Denduluri N, Low JA, Lee JJ at el. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007, 25:3421-3427/
  84. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007, 25:3407-3414.
  85. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS- 247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399-3406.
  86. Cortes J, Vahdat L, Blum JL et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010, 28:3922- 3928.
  87. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009, 27:2954-2961/
  88. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 377:914-923.
  89. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer. Cancer 2001, 92:1759-1768.
  90. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20:2812-2823.
  91. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005, 23:2155-2161.
  92. Blackste in M, Vogel CL, Ambinder R et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002, 62:2-8.
  93. Rha SY, Moon YH, Jeung HC et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005, 90:215-221.
  94. Albain K S, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008, 26:3950-3957.
  95. Mauri D, Kamposioras K, Tsali L et al. Overall survival benefit for weekly vs. three- weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 2009, 36:69-74.
  96. Sparano JA, Vrdoljak E, Rixe O et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010, 28:3256-3263.
  97. Sirohi B, Arnedos M, Popat S et al. Platinum-based chemotherapy in triple negative breast cancer. Ann Oncol 2008, 19:1847-1852.
  98. Wang Z, Hu X, Chen L et al. Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: preliminary results report of a phase II trial [abstract]. J Clin Oncol 2010, 28(suppl):e1100.
  99. Chew HK, Doroshow JH, Frankel P et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009, 27:2163-2169.
  100. Staudacher L, Cottu PH, Diéras V et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011, 22:848-856.
  101. Chung CW, Lee S, Hwang SW, Park EH. Systematic Review of Exercise Effects on Health Outcomes in Women with Breast Cancer. Asian Nursing Research Volume 7, Issue 3, September 2013, Pages 149–159
  102. Ebid AA, El-Sodany AM. Long-term effect of pulsed high-intensity laser therapy in the treatment of post-mastectomy pain syndrome: a double blind, placebo-control, randomized study. Lasers in Medical Science. August 2015, Volume 30, Issue 6, pp 1747–1755
  103. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology. 2013 Mar;46(1):1-11
  104. Lacomba MT, María Sánchez JY, Goñi ÁZ, Merino DPr, Moral OM, Téllez EC, Mogollón EM. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010; 340
  105. Finnane, A., Janda, M., Hayes, S.C. (2015). Review of the evidence of lymphedema treatment effect. American Journal of Physical Medicine and Rehabilitation, 94, 483–498)
  106. Shaw C, Mortimer P, Judd PA: Randomized controlled trial comparing a low- fat diet with a weight-reduction diet in breast cancer-related lymphedema. Cancer 109 (10): 1949-56, 2007
  107. Szuba A, Achalu R, Rockson SG: Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer 95 (11): 2260-7, 2002.
  108. Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. Cancer. 2003 Sep 15;98(6):1114-22.;
  109. Ahmed Omar MT, El Morsy AM, Abd-El-Gayed Ebid A. Treatment of Post- Mastectomy Lymphedema with Laser Therapy: Double Blind Placebo Control Randomized Study. J Surg Res. 2010 Apr 18.)
  110. Piller N, Douglass J, Heidenreich B, Moseley A. Placebo controlled trial of mild electrical stimulation. Journal of Lymphoedema, 2010, Vol 5, No 1 p. 15-25
  111. Грушина Т.И. Реабилитация пациенток после радикального лечения первичного рака молочной железы с помощью методов физической терапии. Физиотерапия Бальнеология Реабилитация, 2011.-N 2.-С.11-17.
  112. Reißhauer A., Schoppe B., Jahr S. Effect of treatment with low-intensity and extremely low-frequency electrostatic fields (DEEP OSCILLATION®) on breast tissue and pain in patients with secondary breast lymphoedema. J Rehabil Med 40:645-650 (2008).
  113. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology. 2013 Mar;46(1):1-11
  114. Howard-Anderson J1, Ganz PA, Bower JE, Stanton AL Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012 Mar 7;104(5):386-405.
  115. García-Manero M, Royo MP, Espinos J, Pina L, Alcazar JL, López G. Pregnancy associated breast cancer. Eur J Surg Oncol. 2009 Feb;35(2):215-8.
  116. Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, Pacini
  117. P. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999 May 5;281(17):1586.
  118. Moschetti I1, Cinquini M, Lambertini M, Levaggi A, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2016 May 27;(5):
  119. Smith TJ1, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG 3rd, Somerfield MR. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999 Mar;17(3):1080-2.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*